Work

Supplementary Figures 1,2,3,4,5 from Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure 1: Ofatumumab and lenalidomide treatment schema. Supplementary Figure 2: Absolute number of responses and response rates in evaluable patients over time. Supplementary Figure 3: FACS plots showing baseline NK and T cell function in HD and CR, PR and NR patients. Supplementary Figure 4: Plasma chemokine and cytokine modulation during ofatumumab and lenalidomide treatment. Supplementary Figure 5: Changes in circulating angiogenic factors during therapy with ofatumumab and lenalidomide.

DOI: 10.1158/1078-0432.22459158

Authors: Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, Alessandra Ferrajoli

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362397336

Cites:

Cited by:

Related to: 10